AGENUS INC Contract Liability (Deferred Revenue)
AGENUS INC (AGEN) had Contract Liability (Deferred Revenue) of $0 as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-03-16
- 2025-12-31: Contract with Customer, Liability, Current $0.00.
- 2025-09-30: Contract with Customer, Liability, Current $45.00K.
- 2025-06-30: Contract with Customer, Liability, Current $45.00K.
- 2025-03-31: Contract with Customer, Liability, Current $14.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 | |
| 2025-09-30 | $45.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $45.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $14.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $31.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $10.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $9.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $13.00K 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $18.00K 10-K · filed 2025-03-17 | |
| 2023-09-30 | $4.99M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $7.83M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $9.89M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $12.27M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $12.76M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $14.20M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $13.53M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $12.43M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $19.68M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $28.15M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $22.83M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $17.19M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $40.12M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $37.34M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $34.22M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $29.17M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $34.23M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $29.54M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $27.24M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $1.81M 10-K · filed 2020-03-16 | $1.81M 10-K · filed 2019-03-18 |
| 2018-09-30 | $843.15K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $946.77K 10-Q · filed 2018-08-09 | |
| 2017-12-31 | $4.48M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |